Can timolol be added to a patient’s regimen of Vyzulta (bimatoprost) and brinzolamide when intra‑ocular pressure remains above target?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Timolol Be Added to Vyzulta and Brinzolamide?

Yes, timolol can be added to your patient's current regimen of Vyzulta (latanoprostene bunod) and brinzolamide when intraocular pressure remains above target. This represents a rational escalation strategy supported by both guideline recommendations and clinical evidence.

Rationale for Adding Timolol

The 2021 Primary Open-Angle Glaucoma guidelines explicitly support this approach 1. Topical beta-adrenergic antagonists like timolol are commonly prescribed for glaucoma and have demonstrated good efficacy and tolerability 1. When target IOP is not achieved with initial therapy, adding medications from different drug classes is the recommended strategy 1.

Mechanism and Expected Benefit

Your patient is currently on:

  • Vyzulta (prostaglandin analog + nitric oxide donor): increases trabecular and uveoscleral outflow
  • Brinzolamide (carbonic anhydrase inhibitor): decreases aqueous production by 15-20% 1

Adding timolol (beta-blocker) would provide complementary IOP reduction through a third mechanism—further decreasing aqueous production 2. This multi-mechanistic approach is precisely what guidelines recommend when monotherapy or dual therapy fails to achieve target pressure 1.

Evidence Supporting This Combination

Multiple studies demonstrate the efficacy of adding timolol to prostaglandin analogs and carbonic anhydrase inhibitors:

  • Timolol added to prostaglandin + brinzolamide: A 2008 study showed that travoprost/timolol fixed combination plus brinzolamide reduced mean diurnal IOP to 17.3 mmHg compared to 22.3 mmHg with prostaglandin alone 3

  • Direct comparison studies: When added to prostaglandin analogs, both timolol and brinzolamide provide similar additional IOP reduction (approximately 4 mmHg), and combining all three is more effective than any two-drug combination 4, 5, 3

  • 24-hour IOP control: Research shows that triple therapy with prostaglandin + carbonic anhydrase inhibitor + beta-blocker provides superior diurnal and nocturnal IOP control 6

Dosing and Administration

According to FDA labeling 2:

  • Start with timolol 0.25% twice daily in the affected eye(s)
  • If response is inadequate after 4 weeks, increase to timolol 0.5% twice daily
  • The concomitant use of two topical beta-blockers is NOT recommended 2

Important timing consideration: Avoid nighttime dosing of beta-blockers, as this is associated with limited efficacy and may contribute to visual field progression via nocturnal reduction of systemic blood pressure 1.

Critical Safety Considerations

Contraindications and Precautions

Before adding timolol, screen for 1:

Absolute contraindications:

  • Asthma or severe chronic obstructive pulmonary disease
  • Sinus bradycardia, second or third-degree AV block
  • Overt cardiac failure
  • Cardiogenic shock

Relative contraindications requiring caution:

  • Diabetes mellitus (may mask hypoglycemia symptoms)
  • Myasthenia gravis
  • Cerebrovascular insufficiency
  • Depression

Monitor for systemic effects:

  • Bradycardia (mean reduction 2.9 beats/minute) 2
  • Decreased blood pressure
  • Bronchospasm in susceptible patients

Common Pitfalls to Avoid

  1. Don't use timolol at bedtime: This reduces efficacy and may worsen nocturnal hypotension 1

  2. Don't combine with another beta-blocker: The FDA label explicitly warns against using two topical beta-blockers simultaneously 2

  3. Don't skip the 4-week evaluation: IOP response to timolol requires several weeks to stabilize; evaluate after approximately 4 weeks 2

  4. Consider cardioselective alternatives: If the patient has mild obstructive airway disease, betaxolol (beta-1 selective) may be safer, though it's less effective for IOP reduction 1

Alternative Considerations

If timolol is contraindicated or not tolerated, consider:

  • Alpha-2 agonists (brimonidine): Though one study showed brimonidine provided less additional IOP reduction than timolol when added to prostaglandin analogs (2.3 mmHg vs 3.9 mmHg reduction) 4
  • Rho kinase inhibitors (netarsudil): Provides 10-20% IOP reduction through increased trabecular outflow 1

Target Pressure Adjustment

Since your patient's IOP remains above target on dual therapy, reassess and potentially lower the target IOP 1. The guidelines recommend a target pressure at least 20% below baseline, but if pressure remains elevated or there's evidence of progression, a more aggressive target (25-30% reduction) may be necessary 1.

Monitor closely: Schedule follow-up in 2-4 weeks after adding timolol to assess IOP response and systemic side effects 7. If target IOP is still not achieved with triple therapy, consider laser trabeculoplasty or surgical intervention 1.

Related Questions

What are the appropriate dosing regimens, contraindications, and monitoring parameters for timolol (both ophthalmic and oral) in the treatment of glaucoma and hypertension?
How do Duotrav (travoprost 0.004%/timolol 0.5% fixed‑combination), Lumigan (bimatoprost 0.01%), and Timoptic XE (timolol 0.5% gel‑forming) compare regarding indications, dosing, efficacy, and adverse effects for intra‑ocular pressure reduction?
Why are prostaglandin analogs now preferred as first‑line therapy over timolol for lowering intra‑ocular pressure?
Can tafluprost (Vyzulta) and brinzolamide (Zolumbus) be used together in this patient to treat elevated intra‑ocular pressure?
What is the recommended dosage of Combigan (brimonidine 0.2%/timolol 0.5% ophthalmic solution) for glaucoma?
In an active 58-year-old individual, is a wide pulse pressure a problem?
What is the preferred route of opioid administration for end-of-life care because it is most convenient and least expensive?
Can tafluprost (Vyzulta) and brinzolamide (Zolumbus) be used together in this patient to treat elevated intra‑ocular pressure?
Why am I feeling a soft, squishy sensation and apparent bulging of nasal cartilage on the side of a prior infection?
For an active 58‑year‑old, is a blood pressure of 120/65 mmHg normal and does it require any treatment?
To which of the following groups does the 2022 revision of the CDC opioid prescribing guidelines apply: hospital patients, patients with sickle cell disease, persons receiving end‑of‑life care, or adults (≥18 years of age)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.